GW Pharmaceuticals

P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

GW Pharmaceuticals balance sheet

Report period2018 2019 2020
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

GW Pharmaceuticals cash flows

Report period2018 2019 2020
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

GW Pharmaceuticals multipliers

Report period2018 2019 2020
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

GW Pharmaceuticals profitability

Report period2018 2019 2020
ROA
ROE
ROS
EBITDA Margin
Operating margin
GW Pharmaceuticals assets
GW Pharmaceuticals cash flows
GW Pharmaceuticals news
25.03.2022
GW Pharmaceuticals and Jazz Pharmaceuticals will build a new manufacturing facility in Kent Science Park, Sittingbourne. The facility will produce two cannabis-based drugs as well as new drugs. Production is scheduled to begin in 2024. The investment will be $100 million.
05.05.2021
Jazz Pharmaceuticals has completed its merger with GW Pharmaceuticals. GW Pharmaceuticals shareholders received $220 for each depositary receipt representing 12 common shares of the company. Of that, $200 in cash and $20 in Jazz common stock.
20.04.2021
GW Pharmaceuticals has received approval from the European Commission for the use of Epidyolex, a cannabis-based drug, as an adjunctive treatment for seizures in children 2 years and older.
16.02.2021
GW Pharmaceuticals' GAAP loss for 2020 was $58.128 million, up 6.4 times from $9.019 million in the previous year. Revenue increased 69.3% to $527.205 million, up from $311.332 million a year earlier.
General information
Company nameGW Pharmaceuticals
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressSOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE CB24 9BZ X0 00000 44 1223 266800
Mailing addressSOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE CB24 9BZ X0 00000
Websitewww.gwpharm.com
Information disclosurewww.sec.gov